SCHEMBL4185878

SCHEMBL4185878

C[C@@H](CC1CCCC1)NCc1ccccc1NS(=O)(=O)c1ccc(-c2cnn(C)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
PKM P14618 1/20 0.45
UCHL1 P09936 1/20 0.40
USP30 Q70CQ3 1/20 0.40
LMNA P02545 6/20 0.38
POLB P06746 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
NMT1 P30419 1/20 0.37
MAPT P10636 6/20 0.37
ALDH1A1 P00352 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.36
GAA P10253 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
BRD4 O60885 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
MEN1 O00255 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192690 0.99 KDM4E (0.46) KDM4EPKMUCHL1USP30LMNA
SCHEMBL4200138 0.86 KDM4E (0.47) KDM4EPKMUCHL1USP30LMNA
SCHEMBL4194965 0.85 KDM4E (0.48) KDM4EPKMUCHL1USP30LMNA
SCHEMBL4197224 0.85 KDM4E (0.46) KDM4EPKMLMNAPOLBMAPT
SCHEMBL4203511 0.84 KDM4E (0.47) KDM4EPKMLMNAPOLBMAPT
SCHEMBL4193027 0.84 KDM4E (0.36) KDM4EPKMALDH1A1SMN1; SMN2BRD4
SCHEMBL4200119 0.83 POLB (0.47) KDM4EPKMLMNAPOLBMAPT
SCHEMBL12050344 0.83 KDM4E (0.55) KDM4EPKMLMNAPOLBMAPT
SCHEMBL4198221 0.82 KDM4E (0.43) KDM4EPKMLMNAPOLBNMT1
SCHEMBL4198111 0.82 KDM4E (0.47) KDM4EPKMLMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 KDM4E 3328/4885PKM 1855/4885UCHL1 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.